In the subgroup of SLE patients with at least moderate disease activity (SELENA-SLEDAI ≥ 4), we observed a significant reduction in GCW and a considerable elevation of both hs-cTnI and NT-proBNP levels compared to the low disease activity counterparts. This evidence concerns the gene TNNI3 and systemic lupus erythematosus.